| Should intraoperative cell-salvaged blood be used in patients with suspected or known malignancy? | |
| | |
MedLine Citation:
|
PMID: 22996966 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
PURPOSE: Intraoperative cell salvage (ICS) is used as an alternative to allogeneic blood transfusion in an attempt to avoid or minimize the risks associated with allogeneic blood. Intraoperative cell salvage is generally avoided in surgeries where malignancy is confirmed or suspected due to concern for potential metastasis or cancer recurrence. The application of post-processing methods for ICS is hypothesized to eliminate this potential risk. The purpose of this narrative review is to examine the in vitro experimental evidence as it pertains to the removal of tumour cells from ICS blood and to review the clinical studies where ICS blood has been used in patients with malignancy. SOURCE: A search of the English literature for relevant articles published from 1973 to 2012 was undertaken using MEDLINE and Cochrane databases. Bibliographies were cross-referenced to locate further studies. PRINCIPAL FINDINGS: Leukoreduction filters are an effective method for removal of malignant cells from ICS blood. Small non-randomized clinical studies to date do not show evidence of an increased rate of metastasis or cancer recurrence. Although a theoretical risk of disease recurrence persists, the decision to use autologous ICS blood must be weighed against the known risks of allogeneic blood transfusion. CONCLUSION: Transfusion of autologous blood harvested via ICS should be considered a viable option for reduction or avoidance of allogeneic product during many oncologic surgeries and may be a lifesaving option for those patients who refuse allogeneic blood products. |
| | |
Authors:
|
Jacqueline D Trudeau; Terrence Waters; Kate Chipperfield |
Related Documents
:
|
17586576 - Characterization of the threshold response of initiation of blood clotting to stimulus ... 23049336 - Analysis of immediate transfusion incidents reported in a regional blood bank. 12377606 - Preparation and biocompatibility of tissue-engineered scaffold materials based on colla... 8341726 - Lipoproteins from normolipidemic and dyslipidemic subjects modify the thromboxane a2 ge... 7573576 - Angiotensin ii and cardiovascular regulation in a freshwater teleost, anguilla rostrata... 9540916 - Halothane-induced intrahepatic portovenous shunting reduces hepatic microvascular sinus... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-9-21 |
Journal Detail:
|
Title: Canadian journal of anaesthesia = Journal canadien d'anesthesie Volume: - ISSN: 1496-8975 ISO Abbreviation: Can J Anaesth Publication Date: 2012 Sep |
Date Detail:
|
Created Date: 2012-9-21 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8701709 Medline TA: Can J Anaesth Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, 3300-910 West 10th Avenue, Vancouver, BC, V5Z 1M9, Canada, jtrudeau@interchange.ubc.ca. |
Vernacular Title:
|
Les cellules sanguines épargnées en peropératoire doivent-elles être réutilisées chez des patients ayant des processus malins connus ou suspectés? |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Carbon Nanotubes Enhance Metastatic Growth of Lung Carcinoma via Up-Regulation of Myeloid-Derived Su...
Next Document: A universal nanoparticle cell secretion capture assay.